EBT-107

A Dual-guide RNA Treatment for Hepatitis B

Excision BioTherapeutics’ EBT-107 program is intended to treat individuals with hepatitis B (HBV) by targeting HBV-infected cells in the liver.

Our Pipeline

Other

EBT-107

HBV non-viral CRISPR/Cas dual gRNA Therapeutic

Discovery/Validation	Preclinical	Cleared IND	Clinical Trials
Discovery/Validation Phase in progress	Preclinical Phase not started	Cleared IND Phase not started	Clinical Trials Phase not started

$50 Billion Market Opportunity

~1.2 million in the U.S.

~350 million patients worldwide¹

^{1) CDC,}^{https://www.cdc.gov/hepatitis/hbv/pdfs/hepbatrisk.pdf}^{. 2021.}

Other Pipeline Programs

EBT-101

Targeting HIV-infected cells in viral tissue reservoirs and systemic circulation.

Learn More

EBT-104

Targeting herpes virus-infected cells in peripheral nervous system (PNS) ganglia.

Learn More

The Innovative Technology That Drives Our Programs

Our cutting-edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

More About Our Technology

Research & Publications

View our library of publications for more information on the research behind our CRISPR gene-editing technology.

View Publications